<HTML>
<HEAD>
<TITLE>Filed by Bowne Pure Compliance</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): October 29, 2008</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>BioCryst Pharmaceuticals, Inc.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>DELAWARE</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>000-23186</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>62-1413174</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>2190 Parkway Lake Drive, Birmingham, Alabama<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>35244</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(205) 444-4600</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>NOT APPLICABLE<BR></B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="left" style="font-size: 10pt"><B>Item&nbsp;5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.</B>


<P align="left" style="font-size: 10pt"><B>Certificate of Incorporation</B>


<P align="left" style="font-size: 10pt; text-indent: 4%">Pursuant to Section 151(g) of the Delaware General Corporation Law (&#147;DGCL&#148;) and Article&nbsp;FOURTH of the Company&#146;s
Third Restated Certificate of Incorporation, the Board of Directors (the &#147;Board&#148;) of BioCryst Pharmaceuticals Inc. (the
&#147;Company&#148;) approved an increase in the authorized number of shares of Series&nbsp;B Junior Participating Preferred Stock
from 45,000 to 95,000. A Certificate of Increase was filed with the Delaware Department of State and became effective
on November&nbsp;3, 2008. The filing of the Certificate of Increase amended the first paragraph of Article&nbsp;FOURTH the
Company&#146;s Third Restated Certificate of Incorporation. Under Section 151(g) of the DGCL and Article&nbsp;FOURTH of the
Company&#146;s Third Restated Certificate of Incorporation, stockholder approval of this action was not required.


<P align="left" style="font-size: 10pt; text-indent: 4%">This summary is subject to and qualified in its entirety by reference to the text of the Certificate of Increase,
which is included as Exhibit&nbsp;3.1 to this filing and is incorporated in this Item&nbsp;5.03 by reference.


<P align="left" style="font-size: 10pt"><B>By-Laws</B>


<P align="left" style="font-size: 10pt; text-indent: 4%">On October&nbsp;29, 2008, the Board amended and restated the Company&#146;s By-laws, effective immediately. A summary of
the principal amendments to the By-laws approved by the Board is set forth below.


<P align="left" style="font-size: 10pt"><U>Advance Notice of Stockholder Nominations of Directors and Other Business</U>: The By-laws were revised to add an
advance notice provision governing the submission to the Company of notice of a stockholder&#146;s intention to propose
director nominations and other business in connection with a meeting of stockholders. The advance notice provisions
are intended to provide stockholders and the Company a reasonable opportunity to consider nominations and other
business proposed to be brought before meetings of stockholders. Among other things, the advance notice provisions:


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Specify deadlines for stockholders to submit notice of director nominations and other business;</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Require stockholders to provide specified information about their ownership of the Company&#146;s securities and
specified information about director nominees and other business;</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Clarify that the advance notice process is separate from the Rule&nbsp;14a-8 stockholder proposal process under the
federal proxy rules; and</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Require that a stockholder, or the stockholder&#146;s qualified representative, appear in person at a meeting of
stockholders to present a nomination or other business. (Section&nbsp;1.10)</TD>
</TR>

</TABLE>


<P align="left" style="font-size: 10pt">As a result of the By-law amendment relating to advance notice of stockholder nominations of directors and other
business, if any stockholder intends to nominate a director candidate or present other business (not including a
proposal submitted for inclusion in the Company&#146;s proxy materials pursuant to Rule&nbsp;14a-8 promulgated under the
Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;)) at the 2009 Annual Meeting of Stockholders, the
stockholder must deliver a notice to the Company&#146;s Secretary at the principal executive offices of the Company. The
notice must be delivered not later than the close of business on the 90th&nbsp;day nor earlier than the close of business on
the 120th&nbsp;day prior to the first anniversary of the preceding year<B>&#146;</B>s annual meeting, subject to limited exceptions if
the annual meeting is more than 30&nbsp;days before or after the anniversary date. Based on the Company&#146;s 2008 annual
meeting date of May&nbsp;21, 2008, the notice must be delivered to the Company no later than the close of business on
February&nbsp;20, 2009, and no earlier than the close of business on January&nbsp;21, 2009 for the 2009 Annual Meeting of
Stockholders. The notice must comply with the applicable requirements of the Amended and Restated By-laws.







<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">





<P align="left" style="font-size: 10pt">Stockholder proposals submitted pursuant to Rule&nbsp;14a-8 promulgated under the Exchange Act must be received by the
Company on or before December&nbsp;17, 2008 in order to be considered for inclusion in the proxy statement relating to the
2009 Annual Meeting of Stockholders.


<P align="left" style="font-size: 10pt"><U>Notice of Regular Board meetings</U>: The By-laws were revised to eliminate the requirement to notify a director of
the time and place of regular board meetings if that director was not present at the time the determination was made.
(Section&nbsp;2.7)


<P align="left" style="font-size: 10pt"><U>Chairman of the Board and Vice-Chairman of the Board</U>: The By-laws were revised to move provisions relating to
the positions of Chairman of the Board and Vice-Chairman of the Board from Article&nbsp;III, which relates to officers, to
Article&nbsp;II, which relates to directors, to clarify that the Chairman of the Board and Vice-Chairman of the Board are
not officer positions. In addition, the By-laws were revised to update the description of the role of the Chairman of
the Board. (Sections&nbsp;2.16, 3.7)


<P align="left" style="font-size: 10pt"><U>Officers of the Company</U>: The By-laws were revised to include the Chief Executive Officer in the list of
officers of the Company to reflect current Company practice. (Section&nbsp;3.1)


<P align="left" style="font-size: 10pt"><U>Indemnification</U>: The By-laws were revised to provide procedures for obtaining indemnification and advancement
of expenses, to address the enforcement of such rights and to otherwise clarify the scope and nature of indemnification
rights granted by the Company. (Article&nbsp;5)


<P align="left" style="font-size: 10pt"><U>Other Changes</U>: The remaining amendments to the By-laws were immaterial language changes, clarifying or
conforming changes, or changes to conform the By-laws to the Third Restated Certificate of Incorporation or the DGCL.


<P align="left" style="font-size: 10pt; text-indent: 4%">This summary is subject to and qualified in its entirety by reference to the text of the Amended and Restated
By-laws, which are included as Exhibit&nbsp;3.2 to this filing and are incorporated in this Item&nbsp;5.03 by reference.


<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">3.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certificate of Increase.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">3.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By-laws of BioCryst Pharmaceuticals, Inc. as amended on October&nbsp;29,
2008.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>






<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">





<P align="center" style="font-size: 10pt">&nbsp;<BR>
<B>SIGNATURE</B><BR>
&nbsp;



<P align="left" style="font-size: 10pt; text-indent: 4%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized.

&nbsp;
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" colspan="3"><B>BioCryst Pharmaceuticals, Inc.</B><BR>&nbsp;<BR></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date: November&nbsp;4, 2008
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Alane Barnes</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Alane Barnes</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">General Counsel</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">4
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">





<P align="center" style="font-size: 10pt"><B>EXHIBIT INDEX</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">3.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certificate of Increase.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">3.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By-laws of BioCryst Pharmaceuticals, Inc. as amended on October&nbsp;29, 2008.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>





<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">5




</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c76716e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 17736}]
{"company-data": {"conformed-name": "BIOCRYST PHARMACEUTICALS INC", "cik": "0000882796", "assigned-sic": "2836", "irs-number": "621413174", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-23186", "film-number": "081160676"}, "business-address": {"street1": "2190 PARKWAY LAKE DR", "city": "BIRMINGHAM", "state": "AL", "zip": "35244", "phone": "2054444600"}, "mail-address": {"street1": "2190 PARKWAY LAKE DR", "city": "BIRMINGHAM", "state": "AL", "zip": "35244"}}
Filed by Bowne Pure Compliance
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 29, 2008
BioCryst Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
DELAWARE
000-23186
62-1413174
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
2190 Parkway Lake Drive, Birmingham, Alabama
35244
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
(205) 444-4600
NOT APPLICABLE
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
Certificate of Incorporation
Pursuant to Section 151(g) of the Delaware General Corporation Law ("DGCL") and Article FOURTH of the Company's
Third Restated Certificate of Incorporation, the Board of Directors (the "Board") of BioCryst Pharmaceuticals Inc. (the
"Company") approved an increase in the authorized number of shares of Series B Junior Participating Preferred Stock
from 45,000 to 95,000. A Certificate of Increase was filed with the Delaware Department of State and became effective
on November 3, 2008. The filing of the Certificate of Increase amended the first paragraph of Article FOURTH the
Company's Third Restated Certificate of Incorporation. Under Section 151(g) of the DGCL and Article FOURTH of the
Company's Third Restated Certificate of Incorporation, stockholder approval of this action was not required.
This summary is subject to and qualified in its entirety by reference to the text of the Certificate of Increase,
which is included as Exhibit 3.1 to this filing and is incorporated in this Item 5.03 by reference.
By-Laws
On October 29, 2008, the Board amended and restated the Company's By-laws, effective immediately. A summary of
the principal amendments to the By-laws approved by the Board is set forth below.
Advance Notice of Stockholder Nominations of Directors and Other Business
: The By-laws were revised to add an
advance notice provision governing the submission to the Company of notice of a stockholder's intention to propose
director nominations and other business in connection with a meeting of stockholders. The advance notice provisions
are intended to provide stockholders and the Company a reasonable opportunity to consider nominations and other
business proposed to be brought before meetings of stockholders. Among other things, the advance notice provisions:
•
Specify deadlines for stockholders to submit notice of director nominations and other business;
•
Require stockholders to provide specified information about their ownership of the Company's securities and
specified information about director nominees and other business;
•
Clarify that the advance notice process is separate from the Rule 14a-8 stockholder proposal process under the
federal proxy rules; and
•
Require that a stockholder, or the stockholder's qualified representative, appear in person at a meeting of
stockholders to present a nomination or other business. (Section 1.10)
As a result of the By-law amendment relating to advance notice of stockholder nominations of directors and other
business, if any stockholder intends to nominate a director candidate or present other business (not including a
proposal submitted for inclusion in the Company's proxy materials pursuant to Rule 14a-8 promulgated under the
Securities Exchange Act of 1934, as amended (the "Exchange Act")) at the 2009 Annual Meeting of Stockholders, the
stockholder must deliver a notice to the Company's Secretary at the principal executive offices of the Company. The
notice must be delivered not later than the close of business on the 90th day nor earlier than the close of business on
the 120th day prior to the first anniversary of the preceding year
'
s annual meeting, subject to limited exceptions if
the annual meeting is more than 30 days before or after the anniversary date. Based on the Company's 2008 annual
meeting date of May 21, 2008, the notice must be delivered to the Company no later than the close of business on
February 20, 2009, and no earlier than the close of business on January 21, 2009 for the 2009 Annual Meeting of
Stockholders. The notice must comply with the applicable requirements of the Amended and Restated By-laws.
Stockholder proposals submitted pursuant to Rule 14a-8 promulgated under the Exchange Act must be received by the
Company on or before December 17, 2008 in order to be considered for inclusion in the proxy statement relating to the
2009 Annual Meeting of Stockholders.
Notice of Regular Board meetings
: The By-laws were revised to eliminate the requirement to notify a director of
the time and place of regular board meetings if that director was not present at the time the determination was made.
(Section 2.7)
Chairman of the Board and Vice-Chairman of the Board
: The By-laws were revised to move provisions relating to
the positions of Chairman of the Board and Vice-Chairman of the Board from Article III, which relates to officers, to
Article II, which relates to directors, to clarify that the Chairman of the Board and Vice-Chairman of the Board are
not officer positions. In addition, the By-laws were revised to update the description of the role of the Chairman of
the Board. (Sections 2.16, 3.7)
Officers of the Company
: The By-laws were revised to include the Chief Executive Officer in the list of
officers of the Company to reflect current Company practice. (Section 3.1)
Indemnification
: The By-laws were revised to provide procedures for obtaining indemnification and advancement
of expenses, to address the enforcement of such rights and to otherwise clarify the scope and nature of indemnification
rights granted by the Company. (Article 5)
Other Changes
: The remaining amendments to the By-laws were immaterial language changes, clarifying or
conforming changes, or changes to conform the By-laws to the Third Restated Certificate of Incorporation or the DGCL.
This summary is subject to and qualified in its entirety by reference to the text of the Amended and Restated
By-laws, which are included as Exhibit 3.2 to this filing and are incorporated in this Item 5.03 by reference.
Item 9.01. Financial Statements and Exhibits.
Exhibit
Number
Description
3.1
Certificate of Increase.
3.2
By-laws of BioCryst Pharmaceuticals, Inc. as amended on October 29,
2008.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized.
BioCryst Pharmaceuticals, Inc.
Date: November 4, 2008
By:
/s/ Alane Barnes
Name:
Alane Barnes
Title:
General Counsel
EXHIBIT INDEX
Exhibit
Number
Description
3.1
Certificate of Increase.
3.2
By-laws of BioCryst Pharmaceuticals, Inc. as amended on October 29, 2008.